The effect of Granulocyte Colony-Stimulating Factor (G-CSF) on endometrial thickness

The effect of intrauterine infusion of Granulocyte Colony-Stimulating Factor (G-CSF) on endometrial thickness in frozen embryo transfer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017030722206N3

Enrollment

Registered

2017-05-01

Start date

2017-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility and treatment methods. Female infertility

Interventions

Intervention 1: Intervention group : intrauterine injection of 300 microgram Granulocyte colony-stimulating factor (G-CSF) in tenth day of hormone replacement therapy (HRT cycle). Intervention 2: Cont

Treatment - Drugs

Intervention group : intrauterine injection of 300 microgram Granulocyte colony-stimulating factor (G-CSF) in tenth day of hormone replacement therapy (HRT cycle)

Control group: not intrauterine injection of Granulocyte colony-stimulating factor (G-CSF), prescription of Estradiol valerate from second day of menstrual cycle and increasing dose (2 mg, every 4)

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Infertile women, Age between 20-45, women are receiving conventional treatment: estradiol valerate , women with normal endometrial thickness (more than 6 mm) for control group and women with endometrial thickness less than 6 mm for intervention group Exclusion criteria: Presence of Granulocyte colony, stimulating factor (G-CSF) contra-indications including: Sickle cell anemia, Chronic neutropenia, Past history of malignancy, Presence of malignancy, Upper respiratory infections, History of uterine surgery, Renal failure, Azoospermia in patient's husband, Pneumonia, Congenital fructose intolerance, Thyroid diseases , Diabetes, Asherman syndrome

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Endometrial thickness. Timepoint: Before intervention and 72 hours after intervention. Method of measurement: Transvaginal sonography.	—

Secondary

Measure	Time frame
Clinical pregnancy. Timepoint: 3 weeks after positive serum ßhCG. Method of measurement: Vaginal ultrosonography.;Implantation rate. Timepoint: 14 days after embryo transfer. Method of measurement: Measurement of serum ßhCG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shima Talebi

Shiraz University of Medical Sciences

stud2480307603@sums.ac.ir+98 71 3233 2365

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026